Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Product information and disease descriptionProduct descriptionProduct information

Product comparison

21 evidence topics · 15 sources

Indirect comparison of recombinant C1 esterase inhibitor with sebetralstat funded by Pharming

“In the primary analysis, rhC1-INH was associated with a statistically significant 4.5-fold increased likelihood of achieving complete resolution (HR 4.52; 95% CI 2.84–7.18) and a significant 82% reduction in redosing (OR 0.18; 95% CI 0.06–0.53) vs sebetralstat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All patients in the rhC1-INH trials had a severe or very severe attack at baseline based on the PGI-S scale [3, 4], whereas patients enrolled in the KONFIDENT trial had a range of baseline attack severities, with only 17.5% of patients having severe or very severe attacks at baseline [8].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The rhC1-INH trials required clinic visits for assessment and treatment, resulting in delayed rhC1-INH administration (median 242 min) [3, 4], whereas the KONFIDENT trial allowed for self-administration of sebetralstat (median 41 min) [8].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In these scenario analyses, the HRs for TTCR were 1.41 (95% CI 0.63–3.18) and 9.76 (95% CI 4.94–19.29).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Rapid Service and Open Access fees were funded by Pharming Healthcare, Inc., Warren, NJ, USA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote